The present study evaluates the potential of Sar
gassum muticum (Sar) and Jan
ia rubens (Jan) seaweeds for enhancing growth and mitigating soil-salinity in chickpea (Cicer arietinum L.). Under control conditions, Sar and Jan extracts improved chickpea growth which was attributed to their potential for increasing photosynthetic pigments, K+ and amino acids, particularly proline, in comparison with water-sprayed control. Upon stress imposition, chickpea growth was reduced in NaCl concentration-dependent manner, and principal component analysis (PCA) revealed Na+ accumulation and oxidative damage as major determinants of sensitivity at high salinity. Furthermore, amino acid quantification indicated activation/deactivation of overall metabolism in roots/shoots, as an adaptive strategy, for maintaining plant growth under salt stress. Sar and Jan extract supplementations provided stress amelioration, and PCA confirmed that improved growth parameters at high salinity were associated with enhanced activities of superoxide dismutase and peroxidase. Besides, four key amino acids, including serine, threonine, proline and aspartic acids, were identified from roots which maximally contribute to Sar- and Jan-mediated stress amelioration. Sar showed higher effectiveness than Jan under both control and salt stress conditions. Our findings highlight “bio-stimulant” properties of two seaweeds and provide mechanistic insight into their salt-ameliorating action which is relevant for both basic and applied research.
LC-MS-assisted metabolomic profiling of the Red Sea-derived brown algae Sargassum cinereum “Sargassaceae” dereplicated eleven compounds 1–11. Further phytochemical investigation afforded two new aryl cresol 12–13, along with eight known compounds 14–21. Both new metabolites, along with 19, showed moderate in vitro antiproliferative activity against HepG2, MCF-7, and Caco-2. Pharmacophore-based virtual screening suggested both 5-LOX and 15-LOX as the most probable target linked to their observed antiproliferative activity. The in vitro enzyme assays revealed 12 and 13 were able to inhibit 5-LOX more preferentially than 15-LOX, while 19 showed a convergent inhibitory activity toward both enzymes. Further in-depth in silico investigation revealed the molecular interactions inside both enzymes’ active sites and explained the varying inhibitory activity for 12 and 13 toward 5-LOX and 15-LOX.
Malaria is one of the most important infectious diseases worldwide. The causative of the most severe forms of malaria, Plasmodium falciparum, has developed resistances against all the available antimalarial drugs. In the present study, the phytochemical investigation of the green seaweed Halimeda macroloba has afforded two new compounds 1–2, along with 4 known ones 3–6. The structures of the compounds had been confirmed using 1& 2D-NMR and HRESIMS analyses. Extensive machine-learning-supported virtual-screening suggested cytochrome-C enzyme as a potential target for compound 2. Docking, absolute-binding-free-energy (ΔGbinding) and molecular-dynamics-simulation (MDS) of compound 2 revealed the strong binding interaction of this compound with cytochrome-C. In vitro testing for crude extract and isolated compounds revealed the potential in vitro inhibitory activity of both extract and compound 2 against P. falciparum. The crude extract was able to inhibit the parasite growth with an IC50 value of 1.8 ± 0.35 µg/mL. Compound 2 also showed good inhibitory activity with an IC50 value of 3.2 ± 0.23 µg/mL. Meanwhile, compound 6 showed moderate inhibitory activity with an IC50 value of 19.3 ± 0.51 µg/mL. Accordingly, the scaffold of compound 2 can be considered as a good lead compound for the future development of new antimalarial agents.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.